Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
7/1/25 | Beckley | BPL-003 for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
6/30/25 | Arcturus (ARCT) | LUNAR-OTC for Ornithine Transcarbamylase (OTC) Deficiency | Subscribers Only | Subscribers Only | Subscribers Only |
6/30/25 | Amgen (AMGN) | Bemarituzumab for Gastric Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/26/25 | Abbisko Therapeutics | ABSK011 for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) | Subscribers Only | Subscribers Only | Subscribers Only |
6/26/25 | Altimmune (ALT) | Pemvidutide for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/20/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/02/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |